Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064220 · ClinicalTrials.gov registry record · Phase 2
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064220: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00064220 is a Phase 2 study that has completed, run by Daiichi Sankyo. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064220, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.
Interventions
- DRUG soblidotin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00064220 record still lists
NCT00064220 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which soblidotin is the first listed.
NCT00064220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00064220 about?
NCT00064220 is a clinical study titled "Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.
What is the current status of trial NCT00064220?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-04. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00064220?
The interventions under investigation include: soblidotin (DRUG).
Who is sponsoring clinical trial NCT00064220?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia